Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Michel Dahan sold 1,398 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $27,456.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Michel Dahan also recently made the following trade(s):

  • On Thursday, September 28th, Michel Dahan sold 5,000 shares of Akebia Therapeutics stock. The shares were sold at an average price of $19.30, for a total value of $96,500.00.
  • On Tuesday, August 15th, Michel Dahan sold 5,000 shares of Akebia Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $75,000.00.

Shares of Akebia Therapeutics, Inc. (NASDAQ AKBA) traded down 0.52% during midday trading on Wednesday, reaching $19.23. The company had a trading volume of 297,370 shares. The company’s market capitalization is $351.91 million. The company’s 50 day moving average price is $16.97 and its 200-day moving average price is $13.75. Akebia Therapeutics, Inc. has a 52 week low of $7.16 and a 52 week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.36. The company had revenue of $28.52 million for the quarter, compared to analysts’ expectations of $26.50 million. On average, equities research analysts predict that Akebia Therapeutics, Inc. will post ($2.57) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Michel Dahan Sells 1,398 Shares of Akebia Therapeutics, Inc. (AKBA) Stock” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/michel-dahan-sells-1398-shares-of-akebia-therapeutics-inc-akba-stock/1608620.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership increased its holdings in Akebia Therapeutics by 165.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 38,900 shares of the biopharmaceutical company’s stock worth $559,000 after purchasing an additional 24,222 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Akebia Therapeutics during the 2nd quarter worth about $159,000. RA Capital Management LLC purchased a new stake in Akebia Therapeutics during the 2nd quarter worth about $12,018,000. State Street Corp increased its holdings in Akebia Therapeutics by 72.9% during the 2nd quarter. State Street Corp now owns 946,888 shares of the biopharmaceutical company’s stock worth $13,604,000 after purchasing an additional 399,160 shares during the period. Finally, DAFNA Capital Management LLC increased its holdings in Akebia Therapeutics by 92.7% during the 2nd quarter. DAFNA Capital Management LLC now owns 135,738 shares of the biopharmaceutical company’s stock worth $1,951,000 after purchasing an additional 65,283 shares during the period. Institutional investors own 57.62% of the company’s stock.

Several equities analysts have recently commented on the company. Mizuho assumed coverage on Akebia Therapeutics in a research note on Wednesday. They set a “buy” rating on the stock. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a research note on Wednesday, August 9th. Finally, Aegis reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research report on Friday, June 30th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Akebia Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.71.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.